The deal extends the Waltham-based firm’s reach into the antipodes, as Biolab has a significant presence in Australia and New Zealand.
A week after closing a $14 million acquisition, Phase Forward inked a multi-year, multi-million-dollar deal with Novo Nordisk to provide clinical trials software to the Danish pharmaceuticals colossus.
The Waltham clinical trials software provider will supply its InForm electronic data capture platform to the diabetes and hemophilia treatment developer for all of its clinical trials. Novo Nordisk is already using the EDC product in more than 30 countries.
Ninety percent of patients in the first human trial of HeartWare International Inc.‘s left ventricular assist implantable pump survived at least 180 days.
The clinical trial involved 50 patients in the United Kingdom, Austria, Germany and Australia who were implanted with the Framingham-based heart pump maker’s device, designed to enable heart transplant candidates to survive until transplatation.
One of the largest private insurers in the world will no longer cover a test that Cambridge Heart Inc. says can predict the risk of a sudden heart attack.
Indianapolis-based WellPoint changed its stance on the Tewksbury-based diagnostics firm’s Microvolt T-Wave Alternans test, moving it from a covered to a non-covered service. WellPoint cited results from recent clinical trials as one reason for its decision.
Brandie Jefferson, MassDevice staff
Electronic feedback between prosthetic devices and human limbs ensures that a patient’s body doesn’t endure too much pressure.
Dentists use occlusion devices to test and measure the strength of a person’s bite.
Insulin pumps deliver precise doses to patients, without requiring multiple shots each day.
Integral to all of these devices is a 0.004-inch sensor, the specialty of Boston-based Tekscan Inc.
Its sensors, and the accompanying software and data acquisition hardware, are used throughout the medical field and beyond.
Thermo Fisher Scientific showed some strain during the first lap of 2009 under the weight of the worldwide economic crunch.
The Waltham-based laboratory instruments maker revised its outlook for the coming year after posting a 12 percent revenue slide and a 34.5 percent decline in net income for the first quarter, largely on slower sales in its core instrumentation business during the period ended March 31.
Brandie Jefferson, MassDevice staff
Medical devices aren’t just for people. Dogs get glaucoma, too. And, just as in humans, it causes great pain and can lead to blindness.
Glaucoma is a condition in which fluid builds up inside the eyeball, creating pressure that eventually damages the optic nerve.
Fortunately, Healionics has a way to help pups in pain,on display at the 2009 BioMEDevice conference here in Boston.
It’s a tiny piece of material — about 1 cm by ½ cm — made from implantable-grade silicone rubber. The device is surgically inserted into the eye, under the sclera, to provide a pathway for excess fluid to drain.
Microtest Laboratories doubled its DNA testing capacity with the purchase of its second DNA analyzer.
The Agawam-based testing services provider said the new analyzer increases its ability to test medical device manufacturing facilities for hard-to-indentify bacteria, mycoplasm and mold within 24 hours.
Candela Corp. posted third-quarter sales of $29.8 million, down 22.5 percent compared with $38.4 million during the same period last year.
Despite the revenue decline, the Wayland-based cosmetic laser device maker managed to narrow its quarterly net loss to $465,000, compared with a net loss of $2.1 million during the third quarter of 2008.
President and CEO Gerad Puorro, citing the quarter as Candela’s second to see revenues increase, said the company reduced its operating expenses in preparation for a return to growth.
Abiomed Inc.‘s latest heart pump models got the nod to hit the market from the federal Food & Drug Administration.
The federal watchdog agency granted 510(k) approval for the Danvers-based heart pump maker’s Impella 5.0 and Impella LD devices.
That means the minimally-invasive catheter-based pumps are cleared to provide circulatory support for up to six hours, easing the burden on patients’ hearts during serious cardiac events.